Eureka Therapeutics Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 46

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

Eureka Therapeutics General Information

Description

Developer of T-cell immunotherapy platforms designed for the treatment of solid tumors and other malignancies. The company's platforms, including ARTEMIS and E-Alpha, utilize proprietary antibody discovery and T-cell receptor engineering technologies to access cancer-specific targets, enabling healthcare providers to harness the immune system for more effective cancer treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5858 Horton Street
  • Suite 370
  • Emeryville, CA 94608
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 5858 Horton Street
  • Suite 370
  • Emeryville, CA 94608
  • United States
+1 (510)

Eureka Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eureka Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Jun-2026 Completed Clinical Trials - Phase 1
8. Grant 06-Jun-2023 Completed Clinical Trials - Phase 1
7. Later Stage VC 16-May-2023 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series E) 23-Jan-2020 Completed Clinical Trials - Phase 1
5. Later Stage VC 15-Jun-2018 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series D) 22-Jan-2018 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 20-Aug-2014 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 17-Nov-2008 $3.13M $4.8M Completed Startup
1. Early Stage VC (Series A) 11-Jun-2007 $1.67M $1.67M Completed Startup
To view Eureka Therapeutics’s complete valuation and funding history, request access »

Eureka Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B 10,591,690 $0.000100 8% $0.3 $0.3 1x $0.3 12.76%
Series A 8,341,270 $0.000100 8% $0.2 $0.2 1x $0.2 10.05%
To view Eureka Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eureka Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of T-cell immunotherapy platforms designed for the treatment of solid tumors and other malignancies. The compa
Drug Discovery
Emeryville, CA
46 As of 2023

South San Francisco, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eureka Therapeutics Competitors (57)

One of Eureka Therapeutics’s 57 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Genelux Formerly VC-backed Westlake Village, CA
Oxford Biotherapeutics Private Equity-Backed Oxford, United Kingdom
Ayala Pharmaceuticals Corporation Wilmington, DE
You’re viewing 5 of 57 competitors. Get the full list »

Eureka Therapeutics Patents

Eureka Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025145059-A1 Constructs targeting msln ecd and uses thereof Inactive 29-Dec-2023
WO-2025145063-A1 Constructs targeting msln peptide/mhc complexes and uses thereof Inactive 29-Dec-2023
WO-2025145087-A1 Constructs targeting msln peptide/mhc complexes and uses thereof Inactive 29-Dec-2023
WO-2025096433-A1 Constructs targeting prostate-specific membrane antigen (psma) and uses thereof Inactive 30-Oct-2023
EP-4661902-A1 Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof Pending 06-Feb-2023 C07K16/3038
To view Eureka Therapeutics’s complete patent history, request access »

Eureka Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eureka Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
California Institute for Regenerative Medicine Government
Maxpro Ventures Venture Capital Minority
Acorn Campus Taiwan Venture Capital Minority
Lyell Immunopharma Corporation Minority
To view Eureka Therapeutics’s complete investors history, request access »

Eureka Therapeutics Investments (1)

Eureka Therapeutics’s most recent deal was a Joint Venture with Aeon Therapeutics. The deal was made on 01-Jan-2002.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aeon Therapeutics 01-Jan-2002 Joint Venture Drug Discovery
To view Eureka Therapeutics’s complete investments history, request access »

Eureka Therapeutics FAQs

  • When was Eureka Therapeutics founded?

    Eureka Therapeutics was founded in 2006.

  • Where is Eureka Therapeutics headquartered?

    Eureka Therapeutics is headquartered in Emeryville, CA.

  • What is the size of Eureka Therapeutics?

    Eureka Therapeutics has 46 total employees.

  • What industry is Eureka Therapeutics in?

    Eureka Therapeutics’s primary industry is Drug Discovery.

  • Is Eureka Therapeutics a private or public company?

    Eureka Therapeutics is a Private company.

  • What is Eureka Therapeutics’s current revenue?

    The current revenue for Eureka Therapeutics is .

  • How much funding has Eureka Therapeutics raised over time?

    Eureka Therapeutics has raised $171M.

  • Who are Eureka Therapeutics’s investors?

    California Institute for Regenerative Medicine, Maxpro Ventures, Acorn Campus Taiwan, and Lyell Immunopharma have invested in Eureka Therapeutics.

  • Who are Eureka Therapeutics’s competitors?

    CytomX Therapeutics, Marengo Therapeutics, Genelux, Oxford Biotherapeutics, and Ayala Pharmaceuticals are some of the 57 competitors of Eureka Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process